Inside the research

GE HealthCare Technologies Inc.

GEHC Research profile · latest available data

Price overview

$66.63

▲ +0.25 (+0.4%)

52w hi$88.03
52w lo$59.45
Vol4.16M
As of25 Sep 2026

The Verdict

Hold

Our score -0.01

Short-0.20
Medium+0.02
Long+0.29

computed 2026-09-27

Key fundamentals

GE HealthCare Technologies Inc.

Healthcare · Medical Devices

Market cap$30.10B
Enterprise value$38.80B
Trailing P/E15.35x
Forward P/E12.31x
EV / EBITDA10.80x
P / S (ttm)1.43x
Profit margin9.3%
Return on equity19.4%
Revenue growth+5.8%
Earnings growth+16.8%
Debt / equity93.97

Layer Breakdown

LayerRawContribution
Fundamental+0.30
Sector+0.08
Technical-0.29
Earnings+0.00
Sentiment+0.27

macro × 1.00 · 2026-09-27

Business overview

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

United States · www.gehealthcare.com

Risk Metrics

Beta vs SPX1.10
Corr SPX0.51
Annual vol34.9%
Annual ret-9.0%
Sharpe-0.26
Max DD-37.4%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$79.95
High / Low$98.00 / $65.00
Median$80.00
Analysts19
Strong Buy2
Buy10
Hold6
Sell1
Strong Sell0

Recent rating actions

2026-04-30Wells Fargo→ Overweight
2026-04-30JP Morgan→ Neutral
2026-04-30Goldman Sachs→ Neutral
2026-04-30Evercore ISI Group→ Outperform
2026-04-30Citigroup→ Neutral
2026-04-30Barclays→ Equal-Weight

Material Events

DateEvent8-K
2026-07-29Reg FD Disclosure, Exhibitsread
2026-07-29Earnings Release, Exhibitsread
2026-07-23Earnings Release, Officer / Director Change…read
2026-05-11Shareholder Vote, Other Material Eventread
2026-04-29Earnings Release, Exhibitsread
2026-03-17Officer / Director Change, Reg FD Disclosure…read
2026-02-27Material Agreement, Termination of Agreement…read
2026-02-04Earnings Release, Exhibitsread
2025-12-15Material Agreement, Material Obligation…read
2025-12-02Other Material Event, Exhibitsread
2025-10-29Earnings Release, Exhibitsread
2025-07-30Earnings Release, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-05-22Lobo KevinBuy10.00K$641.80K
2026-05-15Bankes JeannetteCEO, Patient Care SolutioWithheld for tax5.54K$346.88K
2026-05-15Rackliffe PhilipCEO, AISGrant16.46K—
2026-05-12Hochman Rodney FBuy1.62K$100.36K
2026-05-08Yang Watkin Phoebe L.Buy1.00K$63.01K
2026-05-07Hochman Rodney FGrant2.69K—
2026-05-07LESJAK CATHERINE AGrant3.59K—
2026-05-07Lobo KevinGrant3.59K—
2026-05-07Madden Anne TGrant3.59K—
2026-05-07Madden Anne TGrant2.28K—

Flow & Concentration

Insider 180d net$805.17K
Insider buys / sells3 / 0
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

Dividends

Yield (TTM)0.16%
$ / share (TTM)$0.11
5y CAGR—

Annual dividend per share

2023$0.09
2024$0.12
2025$0.14
2026$0.07

SEC Filings

DateFormDoc
2026-07-2910-Qview
2026-07-298-Kview
2026-07-298-Kview
2026-07-238-Kview
2026-05-264view
2026-05-194view
2026-05-194view
2026-05-134view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view

The Long Run

FY 2023–2025 · 3 years

LineLatestCAGRTrend
Revenue$19.55B+3.2%
Gross profit$8.21B+6.9%
Operating income$2.44B-6.7%
Net income$2.08B-3.7%

Indices

NASDAQ-100S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$66.20$67.01$65.75$66.634.16M
Sep 24$66.14$66.48$65.19$66.383.97M
Sep 23$66.16$66.46$65.62$66.093.17M
Sep 22$66.28$67.09$66.00$66.273.94M
Sep 21$64.24$65.10$63.71$64.813.50M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →